PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7480071-5 1995 Treatment of the cells with PGI2 or dibutyryl cAMP caused a significant inhibition of the thrombin-induced increase in the albumin permeability. Bucladesine 36-50 coagulation factor II, thrombin Homo sapiens 90-98 18311187-6 2008 KEY RESULTS: Long-term pre-treatment of HUVEC with rolipram or db-cAMP significantly increased ATP-, histamine- and thrombin-induced [Ca(2+)](i) rises. Bucladesine 63-70 coagulation factor II, thrombin Homo sapiens 116-124 15246972-2 2004 Exposure of human umbilical vein endothelial cells to forskolin or dibutyryl cAMP, which increase intracellular cAMP by separate mechanisms, inhibited the thrombin-induced ICAM-1 expression. Bucladesine 67-81 coagulation factor II, thrombin Homo sapiens 155-163 15848222-5 2005 Furthermore, the thrombin-induced phosphorylation of HSP27, p38 MAP kinase and Akt were decreased by dibutyryl-cAMP (DBcAMP). Bucladesine 101-115 coagulation factor II, thrombin Homo sapiens 17-25 15848222-5 2005 Furthermore, the thrombin-induced phosphorylation of HSP27, p38 MAP kinase and Akt were decreased by dibutyryl-cAMP (DBcAMP). Bucladesine 117-123 coagulation factor II, thrombin Homo sapiens 17-25 10978267-5 2000 EGb 761 (20 and 100 mg/L), rolipram (50 micromol/L), and db-cAMP (100 micromol/L) significantly inhibited histamine-, ATP-, and thrombin-induced [Ca(2+)](i) increases in HUVECs without modifying resting [Ca(2+)](i) levels. Bucladesine 57-64 coagulation factor II, thrombin Homo sapiens 128-136 1309427-5 1992 Similar to PAF, alpha-thrombin-exposed sites rapidly closed after addition of the protein kinase C inhibitor staurosporine (1 mumol/L) or dibutyryl cyclic adenosine monophosphate (250 mumol/L). Bucladesine 138-178 coagulation factor II, thrombin Homo sapiens 22-30 1321994-10 1992 Platelets treated with PGE1 or dbcAMP showed a reduced [Ca2+]i increment induced by thrombin as compared to non-treated controls. Bucladesine 31-37 coagulation factor II, thrombin Homo sapiens 84-92 1309828-8 1992 In addition, the inhibitory effect of thrombin on MEG-01 cell growth was mimicked by cAMP level enhancing agents such as forskolin, prostaglandin E1 and Bt2cAMP. Bucladesine 153-160 coagulation factor II, thrombin Homo sapiens 38-46 2458288-1 1988 F9 teratocarcinoma cells secrete the serine protease, tissue plasminogen activator (t-PA), upon differentiation induced in vitro by retinoic acid (RA) or RA and dibutyryl cAMP (RA/dbcAMP). Bucladesine 161-175 coagulation factor II, thrombin Homo sapiens 37-52 2458288-1 1988 F9 teratocarcinoma cells secrete the serine protease, tissue plasminogen activator (t-PA), upon differentiation induced in vitro by retinoic acid (RA) or RA and dibutyryl cAMP (RA/dbcAMP). Bucladesine 180-186 coagulation factor II, thrombin Homo sapiens 37-52 2844190-6 1988 Whereas the stimulation by doxorubicin was not influenced by pretreatment with dibutyryl-cyclic-AMP which inhibits the effects of thrombin, this effect was inhibited by daunorubicin, neomycin and stimulated by the diacylglycerol-kinase inhibitor R 59 022. Bucladesine 79-99 coagulation factor II, thrombin Homo sapiens 130-138 2932474-5 1985 Thrombin-induced secretion of all three proteins was inhibited by prostaglandin E1 and dibutyryl-cyclic AMP. Bucladesine 87-107 coagulation factor II, thrombin Homo sapiens 0-8 6303329-2 1983 Thrombin-induced 1,2-diacylglycerol (DG) formation as a result of phospholipase C activation was inhibited by pretreatment with dibutyryl cAMP (dbcAMP) in a dose-dependent manner. Bucladesine 128-142 coagulation factor II, thrombin Homo sapiens 0-8 2860937-7 1985 The transglutaminase-catalyzed polymer formation following thrombin stimulation of platelets is inhibited by a calcium channel blocker, an intracellular calcium antagonist, as well as other inhibitors such as indomethacin, dibutyryl cyclic AMP, and prostaglandin E1. Bucladesine 223-243 coagulation factor II, thrombin Homo sapiens 59-67 6091292-0 1984 Effects of dibutyryl cyclic AMP and forskolin on phospholipid biosynthesis in thrombin-stimulated human platelets. Bucladesine 11-31 coagulation factor II, thrombin Homo sapiens 78-86 6091292-2 1984 It was found that preincubation with 2.5 mM Bt2cAMP produced a 2-4-fold increase in thrombin-induced incorporation into phospholipids compared to platelets activated by thrombin alone. Bucladesine 44-51 coagulation factor II, thrombin Homo sapiens 84-92 6091292-2 1984 It was found that preincubation with 2.5 mM Bt2cAMP produced a 2-4-fold increase in thrombin-induced incorporation into phospholipids compared to platelets activated by thrombin alone. Bucladesine 44-51 coagulation factor II, thrombin Homo sapiens 169-177 6309278-5 1983 The effect of thrombin was inhibited by preincubation of thrombin with hirudin or antithrombin III plus heparin or by preincubation of the monolayers with dibutyryl cyclic adenosine monophosphate (dbcAMP). Bucladesine 155-195 coagulation factor II, thrombin Homo sapiens 14-22 6309278-5 1983 The effect of thrombin was inhibited by preincubation of thrombin with hirudin or antithrombin III plus heparin or by preincubation of the monolayers with dibutyryl cyclic adenosine monophosphate (dbcAMP). Bucladesine 197-203 coagulation factor II, thrombin Homo sapiens 14-22 6303329-2 1983 Thrombin-induced 1,2-diacylglycerol (DG) formation as a result of phospholipase C activation was inhibited by pretreatment with dibutyryl cAMP (dbcAMP) in a dose-dependent manner. Bucladesine 144-150 coagulation factor II, thrombin Homo sapiens 0-8 214141-2 1978 Thrombin-induced release of arachidonic acid from human platelet phosphatidylcholine is found to be more than 90% impaired by incubation of platelets with 1 mM dibutyryl cyclic adenosine monophosphate (Bt2 cyclic AMP) or with 0.6 mM 8-(N,N-diethylamino)-octyl-3,4,5-trimethoxybenzoate (TMB-8), an intracellular calcium antagonist. Bucladesine 160-200 coagulation factor II, thrombin Homo sapiens 0-8 197570-4 1977 The influence of PGE1 with theophylline, and dibutyryl cyclic AMP on the thrombin induced release of 14C-arachidonic acid from platelet membrane phospholipids was also investigated. Bucladesine 45-65 coagulation factor II, thrombin Homo sapiens 73-81 333455-5 1977 Dibutyryl cyclic AMP inhibits the release reaction, Xa binding, and rate of thrombin generation in parallel. Bucladesine 0-20 coagulation factor II, thrombin Homo sapiens 76-84 164214-5 1975 Drugs that act through cAMP (PGE1, theophylline, dibutyryl-cAMP) slow an early step in the mechanism of thrombin-induced secretion and completely block at higher levels, with the required concentration of inhibitor dependent on thrombin concentration. Bucladesine 49-63 coagulation factor II, thrombin Homo sapiens 104-112 164214-5 1975 Drugs that act through cAMP (PGE1, theophylline, dibutyryl-cAMP) slow an early step in the mechanism of thrombin-induced secretion and completely block at higher levels, with the required concentration of inhibitor dependent on thrombin concentration. Bucladesine 49-63 coagulation factor II, thrombin Homo sapiens 228-236 4331802-6 1972 Prior incubation of platelets with dibutyryl cyclic adenosine monophosphate (AMP), prostaglandin E(1), or theophylline protected adenyl cyclase from inhibition by thrombin. Bucladesine 35-75 coagulation factor II, thrombin Homo sapiens 163-171 4331802-9 1972 This hypothesis is supported by the parallel effects of thrombin on adenyl cyclase activity and thrombin-sensitive protein release in the presence of dibutyryl cyclic AMP, prostaglandin E(1), and theophylline at varying concentrations of thrombin. Bucladesine 150-170 coagulation factor II, thrombin Homo sapiens 56-64 4331802-9 1972 This hypothesis is supported by the parallel effects of thrombin on adenyl cyclase activity and thrombin-sensitive protein release in the presence of dibutyryl cyclic AMP, prostaglandin E(1), and theophylline at varying concentrations of thrombin. Bucladesine 150-170 coagulation factor II, thrombin Homo sapiens 96-104 4331802-9 1972 This hypothesis is supported by the parallel effects of thrombin on adenyl cyclase activity and thrombin-sensitive protein release in the presence of dibutyryl cyclic AMP, prostaglandin E(1), and theophylline at varying concentrations of thrombin. Bucladesine 150-170 coagulation factor II, thrombin Homo sapiens 96-104 190267-5 1977 Incubation of platelets with either dibutyryl cyclic adenosine 3",5"-monophosphate (dBcAMP) or prostaglandin E1 (PGE1) before thrombin addition blocks the subsequent formation of oxygenated products of arachidonic acid including thromboxane A2, thromboxane B2, and malonaldehyde. Bucladesine 84-90 coagulation factor II, thrombin Homo sapiens 126-134 190267-8 1977 Prior treatment of platelets with dBcAMP or PGE1 reverses the thrombin inhibition of the acetylation of cyclo-oxygenase. Bucladesine 34-40 coagulation factor II, thrombin Homo sapiens 62-70 169298-5 1975 Prior incubation of platelets with dibutyryl cyclic adenosine 3",5"-monophosphate or prostaglandin E1 inhibited thrombin-induced peak 7 and peak 9 protein phosphorylation. Bucladesine 35-81 coagulation factor II, thrombin Homo sapiens 112-120 4322665-4 1971 Dibutyryl cyclic AMP inhibited platelet aggregation induced by ADP, epinephrine, collagen, and thrombin. Bucladesine 0-20 coagulation factor II, thrombin Homo sapiens 95-103